A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH (NCT07221188)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Tolerability of Efimosfermin Alfa in Participants With Known or Suspected F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-2)
🩺 Plain-English Summary (8th-Grade Level)
This study will evaluate the safety and tolerability of Efimosfermin Alfa for participants with known or suspected MASH with fibrosis consistent with stage F2 or F3.
Who can join: Review the eligibility criteria below.
Location: GSK Investigational Site — Arcadia, California
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (53 Sites)
Showing the first 25 of 53 sites.
- GSK Investigational Site — Arcadia, California
- GSK Investigational Site — Covina, California
- GSK Investigational Site — Los Angeles, California
- GSK Investigational Site — San Diego, California
- GSK Investigational Site — Santa Maria, California
- GSK Investigational Site — Van Nuys, California
- GSK Investigational Site — Boynton Beach, Florida
- GSK Investigational Site — Cape Coral, Florida
- GSK Investigational Site — Doral, Florida
- GSK Investigational Site — Hialeah, Florida
- GSK Investigational Site — Homestead, Florida
- GSK Investigational Site — Inverness, Florida
- GSK Investigational Site — Jacksonville, Florida
- GSK Investigational Site — Kissimmee, Florida
- GSK Investigational Site — Lakeland, Florida
- GSK Investigational Site — Maitland, Florida
- GSK Investigational Site — Miami, Florida
- GSK Investigational Site — Miami, Florida
- GSK Investigational Site — Miami, Florida
- GSK Investigational Site — Miami, Florida
- GSK Investigational Site — Miami, Florida
- GSK Investigational Site — Miami Lakes, Florida
- GSK Investigational Site — Ocala, Florida
- GSK Investigational Site — Palmetto Bay, Florida
- GSK Investigational Site — Sarasota, Florida
📞 Contact the Study Coordinator
Phone: (877) 379-3718
Email: GSKClinicalSupportHD@gsk.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Non-alcoholic Fatty Liver Disease
- Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis — Chula Vista, California
- Role of Immune System in Obesity-related Inflammation and Cardiometabolic Risk — St Louis, Missouri
- A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017) — Chandler, Arizona
- A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) — Birmingham, Alabama
- SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease — Chicago, Illinois
- The Olmsted NAFLD Epidemiology Study (TONES) — Rochester, Minnesota
Explore by condition: All Non-alcoholic Fatty Liver Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.